Bruker is hosting a webinar that will examine the PIPAc project in more detail. This exciting initiative is reshaping pharmaceutical manufacturing by combining AI, in-line NMR, flow chemistry, and 3D-printed modular reactors.
Attendees will see how AI helps fine-tune chemical reactions in real time, while Bruker’s in-line NMR technology keeps a close eye on the synthesis of active pharmaceutical ingredients (APIs).
The use of continuous flow chemistry, along with compact, 3D-printed reactors, opens the door to mobile and efficient production, making it easier to scale up quickly and adapt to changing needs.
This session is a great opportunity to explore how smart automation, real-time analytics, and innovative reactor design are coming together to make pharmaceutical manufacturing more flexible, efficient, and data-driven.
Register now to learn more about modern pharma manufacturing.
Key learning points
- Smarter Process Control: Discover how AI, in-line NMR, and process analytical technology (PAT) work together to monitor and optimize chemical reactions in real time—ensuring efficient, consistent production of APIs.
- Scalable, Flexible Manufacturing: See how modular 3D-printed reactors and continuous flow chemistry enable fast scale-up and mobile production setups, supporting agile, resource-efficient operations.
- Cutting-Edge Applications: Explore how the latest advancements in flow chemistry, 3D printing, and AI-driven analytics are being applied to improve API synthesis and accelerate pharmaceutical innovation.
What to expect
Explore how the PIPAc project brings together AI, in-line NMR, flow chemistry, and 3D-printed modular reactors to enable compact, mobile production of APIs.
This session will cover real-time process monitoring, continuous flow optimization, and modular reactor design, along with real-world case studies that highlight efficient, scalable, and safe pharmaceutical manufacturing.
Attendees will walk away with practical insights into how these technologies are shaping the future of modern API synthesis.
Who should attend?
This webinar is ideal for pharmaceutical scientists, bioprocess engineers, quality assurance professionals, and anyone involved in pharmaceutical manufacturing and development.
Attendees will gain practical insights into improving process control, ensuring product quality, and applying innovative tools like NMR, PAT, and AI to modernize API production.
About the speakers
Alejandro Bara-Estaún earned his Ph.D. in Inorganic Chemistry from the University of Bath (UK), working in collaboration with the University of Bristol and Evonik (Germany). He went on to complete a two-year postdoctoral position at Bruker, where he led the PIPAc project in partnership with Alysophil, Novalix, and De Dietrich.
Bara-Estaún now serves as Solution Product Manager for (bio)Process and Process Analytical Technology within Bruker’s Biopharma and Applied (BPA) division, focusing on innovative solutions for process monitoring and control in pharmaceutical manufacturing.
Philippe Robin is the co-founder and CEO of Alysophil, a Strasbourg-based company specializing in continuous-flow chemistry solutions enhanced by artificial intelligence for process control. Alysophil is dedicated to improving the efficiency and sustainability of chemical production.
Under Robin’s leadership, the company has launched key initiatives such as Chempocket—modular micro-factories designed for flexible chemical synthesis—and PIPAc, a collaborative program focused on pharmaceutical processes developed with partners including De Dietrich, Bruker, and Novalix.
Robin is passionate about leveraging emerging technologies to help the chemical industry shift toward more agile, efficient, and environmentally responsible production models.
Luis Carrillo is the Managing Director of De Dietrich Group’s subsidiary in Dijon, which focuses on developing engineering solutions by integrating both in-house and third-party technologies. The Dijon site also serves as the Group’s innovation hub, where the PIPAc project plays a central role in shaping future commercial offerings.
A chemist by training, Carrillo holds a degree from the University of Barcelona (Spain) and a Master’s from IESE Business School. Over the past decade, he has held several leadership roles within the De Dietrich Group.
Carrillo is deeply committed to driving sustainable innovation and reinforcing the Group’s position as a leader in advanced chemical engineering solutions.
Guillaume Bentzinger joined Novalix in 2018 as a Junior Project Manager in the Synthetic Chemistry department. A year later, he moved into the Process & Flow department, where he advanced to Project Manager and has since played a key role in developing Novalix’s flow chemistry capabilities. He currently leads the development of flow-based chemistry for the PIPAc project.
Bentzinger studied organic chemistry in Strasbourg at the IUT Robert Schuman Technical Institute and the European School of Chemistry, Polymers and Materials (ECPM). He earned his Ph.D. in medicinal chemistry in 2016 from the University of Picardie Jules Verne in Amiens, under the supervision of Professor Pascal Sonnet and Dr. Alexandra Dassonville-Klimpt. In 2017, he completed postdoctoral research in medicinal chemistry at Almac Discovery and the University of Belfast, working with Dr. Hugues Miel.